Table 2.
Statistical analyses and IC50 values of doxorubicin treatment in Twist-1 or negative siRNA transfected bladder cancer cell lines
| Bladder cancer cell line | IC50 (μg/mL)† |
Two-way anova results |
||||
|---|---|---|---|---|---|---|
| Negative siRNA | Twist-1 siRNA | Treatment | Concentration | Interaction | ||
| F(1,60) | F(5,60) | F(5,60) | P-value | |||
| BIU-87 | 0.53 (0.44–0.62) | 0.18 (0.15–0.22) | 167.49*** | 277.99*** | 6.99*** | <0.001 |
| J82 | 0.96 (0.78–1.14) | 0.18 (0.17–0.23) | 224.82*** | 189.15*** | 12.10*** | <0.001 |
| UM-UC-3 | 0.65 (0.59–0.74) | 0.21 (0.19–0.24) | 131.13*** | 199.56*** | 5.97** | <0.010 |
*
P < 0.01;
**
P < 0.001.
†
IC50 value and 95% confidence interval of doxorubicin in each treatment.